Chemotherapy	chemotherapy	O	O	O	O
of	of	O	O	O	O
advanced	advanced	O	O	O	O
inoperable	inoperable	O	O	O	O
non-small	non-small	O	O	O	O
cell	cell	O	O	O	O
lung	lung	O	O	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
with	with	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
a	a	O	O	O	O
phase	phase	O	O	O	O
II	ii	O	O	O	O
trial	trial	O	O	O	O
.	.	O	O	O	O

Paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
Taxol	taxol	CHEMICALS	O	OTHERS	I
;	;	O	O	O	O
Bristol-Myers	bristol-myers	O	O	O	O
Squibb	squibb	O	O	O	O
Company	company	O	O	O	O
,	,	O	O	O	O
Princeton	princeton	O	O	O	O
,	,	O	O	O	O
NJ	nj	O	O	O	O
)	)	O	O	O	O
has	has	O	O	O	O
demonstrated	demonstrated	O	O	O	O
significant	significant	O	O	O	O
antineoplastic	antineoplastic	O	O	O	O
activity	activity	O	O	O	O
against	against	O	O	O	O
different	different	O	O	O	O
tumor	tumor	O	DISEASE	OTHERS	I
types	types	O	O	O	O
,	,	O	O	O	O
notably	notably	O	O	O	O
ovarian	ovarian	O	O	O	O
and	and	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Two	two	O	O	O	O
phase	phase	O	O	O	O
II	ii	O	O	O	O
trials	trials	O	O	O	O
of	of	O	O	O	O
24-hour	24-hour	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
infusions	infusions	O	O	O	O
in	in	O	O	O	O
chemotherapy-naive	chemotherapy-naive	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
stage	stage	O	O	O	O
IIIB	iiib	O	O	O	O
or	or	O	O	O	O
IV	iv	O	O	O	O
non-small	non-small	O	O	O	O
cell	cell	O	O	O	O
lung	lung	O	O	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
(	(	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
)	)	O	O	O	O
reported	reported	O	O	O	O
response	response	O	O	O	O
rates	rates	O	O	O	O
of	of	O	O	O	O
21	21	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
24	24	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Leukopenia	leukopenia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
dose	dose	O	O	O	O
limiting	limiting	O	O	O	O
:	:	O	O	O	O
as	as	O	O	O	O
many	many	O	O	O	O
as	as	O	O	O	O
62.5	62.5	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
experienced	experienced	O	O	O	O
grade	grade	O	O	O	O
4	4	O	O	O	O
leukopenia	leukopenia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
investigated	investigated	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
a	a	O	O	O	O
3-hour	3-hour	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
infusion	infusion	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
phase	phase	O	O	O	O
II	ii	O	O	O	O
trial	trial	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
inoperable	inoperable	O	O	O	O
stage	stage	O	O	O	O
IIIB	iiib	O	O	O	O
or	or	O	O	O	O
IV	iv	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
58	58	O	O	O	O
patients	patients	O	O	O	O
treated	treated	O	O	O	O
(	(	O	O	O	O
41	41	O	O	O	O
men	men	O	O	O	O
and	and	O	O	O	O
17	17	O	O	O	O
women	women	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
median	median	O	O	O	O
age	age	O	O	O	O
of	of	O	O	O	O
59	59	O	O	O	O
years	years	O	O	O	O
(	(	O	O	O	O
age	age	O	O	O	O
range	range	O	O	O	O
,	,	O	O	O	O
25	25	O	O	O	O
to	to	O	O	O	O
75	75	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
a	a	O	O	O	O
performance	performance	O	O	O	O
status	status	O	O	O	O
of	of	O	O	O	O
0	0	O	O	O	O
through	through	O	O	O	O
2	2	O	O	O	O
.	.	O	O	O	O

Most	most	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
72.4	72.4	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
stage	stage	O	O	O	O
IV	iv	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
225	225	O	O	O	O
mg/m2	mg/m2	O	O	O	O
was	was	O	O	O	O
infused	infused	O	O	O	O
over	over	O	O	O	O
3	3	O	O	O	O
hours	hours	O	O	O	O
every	every	O	O	O	O
3	3	O	O	O	O
weeks	weeks	O	O	O	O
with	with	O	O	O	O
standard	standard	O	O	O	O
prophylactic	prophylactic	O	O	O	O
premedication	premedication	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
50	50	O	O	O	O
patients	patients	O	O	O	O
evaluable	evaluable	O	O	O	O
for	for	O	O	O	O
response	response	O	O	O	O
,	,	O	O	O	O
12	12	O	O	O	O
(	(	O	O	O	O
24	24	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
partial	partial	O	O	O	O
remission	remission	O	O	O	O
,	,	O	O	O	O
26	26	O	O	O	O
(	(	O	O	O	O
52	52	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
no	no	O	O	O	O
change	change	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
12	12	O	O	O	O
had	had	O	O	O	O
disease	disease	O	DISEASE	OTHERS	I
progression	progression	O	DISEASE	OTHERS	I
(	(	O	O	O	O
24	24	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Hematologic	hematologic	O	O	OTHERS	I
toxicities	toxicities	O	DISEASE	OTHERS	I
were	were	O	O	O	O
mild	mild	O	O	O	O
:	:	O	O	O	O
only	only	O	O	O	O
one	one	O	O	O	O
patient	patient	O	O	O	O
(	(	O	O	O	O
2	2	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
developed	developed	O	O	O	O
grade	grade	O	O	O	O
3	3	O	O	O	O
or	or	O	O	O	O
4	4	O	O	O	O
neutropenia	neutropenia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
while	while	O	O	O	O
29	29	O	O	O	O
%	%	O	O	O	O
had	had	O	O	O	O
grade	grade	O	O	O	O
1	1	O	O	O	O
or	or	O	O	O	O
2	2	O	O	O	O
.	.	O	O	O	O

Grade	grade	O	O	O	O
1	1	O	O	O	O
or	or	O	O	O	O
2	2	O	O	O	O
polyneuropathy	polyneuropathy	O	DISEASE	OTHERS	I
affected	affected	O	O	O	O
56	56	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
while	while	O	O	O	O
only	only	O	O	O	O
one	one	O	O	O	O
(	(	O	O	O	O
2	2	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
experienced	experienced	O	O	O	O
severe	severe	O	O	O	O
polyneuropathy	polyneuropathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Similarly	similarly	O	O	O	O
,	,	O	O	O	O
grade	grade	O	O	O	O
1	1	O	O	O	O
or	or	O	O	O	O
2	2	O	O	O	O
myalgia/arthralgia	myalgia/arthralgia	O	O	O	O
was	was	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
63.2	63.2	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
only	only	O	O	O	O
14.3	14.3	O	O	O	O
%	%	O	O	O	O
experienced	experienced	O	O	O	O
grade	grade	O	O	O	O
3	3	O	O	O	O
or	or	O	O	O	O
4	4	O	O	O	O
.	.	O	O	O	O

Nausea	nausea	O	DISEASE	OTHERS	I
and	and	O	O	O	O
vomiting	vomiting	O	DISEASE	OTHERS	I
were	were	O	O	O	O
infrequent	infrequent	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
14	14	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
experiencing	experiencing	O	O	O	O
grade	grade	O	O	O	O
1	1	O	O	O	O
or	or	O	O	O	O
2	2	O	O	O	O
and	and	O	O	O	O
only	only	O	O	O	O
2	2	O	O	O	O
%	%	O	O	O	O
experiencing	experiencing	O	O	O	O
grade	grade	O	O	O	O
3	3	O	O	O	O
or	or	O	O	O	O
4	4	O	O	O	O
.	.	O	O	O	O

Paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
thus	thus	O	O	O	O
an	an	O	O	O	O
active	active	O	O	O	O
single	single	O	O	O	O
agent	agent	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
patient	patient	O	O	O	O
population	population	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
3-hour	3-hour	O	O	O	O
infusion	infusion	O	O	O	O
proving	proving	O	O	O	O
comparably	comparably	O	O	O	O
effective	effective	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
24-hour	24-hour	O	O	O	O
infusion	infusion	O	O	O	O
and	and	O	O	O	O
superior	superior	O	O	O	O
in	in	O	O	O	O
terms	terms	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
hematologic	hematologic	O	O	O	O
and	and	O	O	O	O
nonhematologic	nonhematologic	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Further	further	O	O	O	O
phase	phase	O	O	O	O
II	ii	O	O	O	O
studies	studies	O	O	O	O
with	with	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
combined	combined	O	O	O	O
with	with	O	O	O	O
other	other	O	O	O	O
drugs	drugs	O	O	O	O
active	active	O	O	O	O
against	against	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
are	are	O	O	O	O
indicated	indicated	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
phase	phase	O	O	O	O
III	iii	O	O	O	O
studies	studies	O	O	O	O
comparing	comparing	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
with	with	O	O	O	O
standard	standard	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
remain	remain	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
completed	completed	O	O	O	O
.	.	O	O	O	O

